Moneycontrol PRO
LAMF
LAMF

Surajit Pal

Jump to
  • USFDA issues import alert for Divi's Labs Vizag unit

  • Price erosion won't impact generic cos in US: Dishman Pharma

  • Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

  • Trump's 'Make in US' plan a worry for pharma cos: Surajit Pal

  • Pharma price collusion charges tough to prove: Prabhudas

  • Crack The Code: Decoding pharma sector

  • US FDA completes Aurobindo's Unit 4 audit; to help boost US biz

  • Aurobindo's topline can swell by $350 m with Teva buy: PL

  • Sun Pharma's topline may suffer; like Aurobindo, Glenmark:Expert

  • Pharma biz to drive Jubilant Life's future growth: Surajit Pal

  • Not positive on Lupin's US business: Surajit Pal

  • After DRL-Teva, expect more M&A action in pharma: Prabhudas

  • See Lupin's earnings growing only 8-12%: Prabhudas Lilladher

  • Thyrocare biz looks convincing; subscribe to its IPO: Experts

  • Aim is to prevent rampant use of antibiotics: P Lilladher

  • Ranbaxy effect playing on Sun Pharma's margins: Pros

  • 'Lupin Q4 misses estimates, stock upside potential capped'

  • See 10% overall growth for Sun-Ranbaxy entity: Surajit Pal

  • Hold Sun Pharma, says Surajit Pal

  • Accumulate Sun Pharmaceutical Industries: Surajit Pal

  • Sun Pharma to buy GSK's opiates business in Australia

  • See Sun-Ranbaxy divesting 7 brands by March: Surajit Pal

  • US FDA initiates audit of Ipca's Indore SEZ; sales hit seen

  • Here's how experts read Ranbaxy's Q2FY15 earnings

  • Here's what experts make of Lupin's Q2 earnings

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347